Foghorn Therapeutics Inc. Common Stock
FHTXStock
$5.07−8.50%52W
Market Cap$319.99M
P/E—
Div yield—
Beta2.80
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.45%
Price vs S&P 500 (4W)31.30%
VGM Score46.58
Market Capitalization$319.99M
Earnings Surprise History
Q1 26-0.29est. -0.31
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FHTXFoghorn Therapeutics Inc. Common Stock | D | B | C | $5.07 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Foghorn Therapeutics discovers and develops medicines targeting dependencies in the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is advancing two lead candidates—FHD-286, a selective ATPase inhibitor, and FHD-609, a protein degrader—for the treatment of hematologic cancers and solid tumors.